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Abstract
N-acetyltransferase 2 (NAT2) is an important enzyme involved in the metabolism of a
wide spectrum of naturally occurring xenobiotics, including therapeutic drugs and common
environmental carcinogens. Extensive polymorphism in NAT2 gives rise to a wide
interindividual variation in acetylation capacity which influences individual susceptibility to
various drug-induced adverse reactions and cancers. Striking patterns of geographic
differentiation have been described for the main slow acetylation variants of the NAT2 gene,
suggesting the action of natural selection at this locus. In the present study, we took advantage
of the whole-genome sequence data available from the 1000 Genomes project to investigate
the global patterns of population genetic differentiation at NAT2 and determine whether they
are atypical compared to the remaining variation of the genome. The non-synonymous
substitution c.590G>A (rs1799930) defining the slow NAT2*6 haplotype cluster exhibited an
unusually low FST value when compared to the genome average (FST = 0.006, P-value =
0.016). It was pointed out as the most likely target of a homogenizing process of selection
promoting the same allelic variant in globally distributed populations. The rs1799930 A allele
has been associated with the slowest acetylation capacity in vivo and its substantial correlation
with the subsistence strategy adopted by past human populations suggests that it may have
conferred a selective advantage in populations shifting from foraging to agricultural and
pastoral activities in the Neolithic period. Results of neutrality tests further supported an
adaptive evolution of the NAT2 gene through either balancing selection or directional
selection acting on multiple standing slow-causing variants.

Introduction
The human acetylation polymorphism is one of the oldest and best-characterized
pharmacogenetic traits that underlie interindividual and interethnic differences in response to
xenobiotics. Acetylation catalised by NAT2 is a major biotransformation pathway for
aromatic and heterocyclic amines present in the environment and diet, which can either be
detoxified or bioactivated into metabolites that have the potential to cause toxicity and cancer
(Butcher et al., 2002; Hein, 2002). From the clinical point of view, NAT2 acetylation is
increasingly recognized as associated with significant health problems. Many clinically useful
drugs are excreted by acetylation, some of them being crucial in the treatment of diseases
representing a worldwide concern, such as tuberculosis, AIDS-related complex diseases, and
hypertension. The individual acetylation status has proven to be an important determinant of
both the effectiveness of prescribed medications and the development of adverse drug
reactions and toxicity during drug treatment (Ladero, 2008; Meisel, 2002). Moreover,
epidemiological studies have associated the acetylation phenotype with an increased
susceptibility to various cancers following exposure to aromatic amine carcinogens (Agúndez,
2008; Hein, 2006; Sanderson et al., 2007; Selinski et al., 2013).
N-acetylation activity has been investigated in a wide range of populations, leading to a
phenotype classification of humans in two main categories: fast acetylators, who exhibit the
so-called ‘wild-type’ or normal acetylation activity, and slow acetylators, characterized by a
decreased enzyme activity. The proportions of rapid and slow acetylators vary remarkably
between populations of different ethnic and/or geographic origin (Sabbagh et al., 2011;
Walker et al., 2009; Weber and Hein, 1985). Depending on the test substrate administered, a
trimodal, rather than bimodal, distribution can be observed, revealing an additional,
intermediate phenotype (Cascorbi et al., 1995; Kilbane et al., 1990; Parkin et al., 1997).
Moreover, recent results suggest that the slow acetylator phenotype is not homogeneous and

that several slow acetylator phenotypes may rather exist, resulting from an allelic
heterogeneity and differential functional effects of the slow acetylation alleles (Ruiz et al.,
2012; Selinski et al., 2013). A refinement in phenotype inference, notably by the
consideration of an ‘ultra-slow’ acetylator category, is advocated to help identifying new
clinically relevant associations with one or more of these phenotype subcategories.
Acetylation polymorphism arises from allelic variations in the NAT2 gene, which result in
the production of arylamine N-acetyltransferase 2 (NAT2) proteins with variable enzyme
activity or stability. The NAT2 gene contains two exons with a relatively long intronic region
of about 8.6 kb. Exon 1 is very short (100 bp) and the entire protein-coding region is
contained within the 870-bp exon 2. Extensive polymorphism has been described in exon 2,
with 38 nucleotide variations registered to date (http://nat.mbg.duth.gr/). Of these, four
common non-synonymous substitutions at positions 191, 341, 590 and 857 are the most
studied and characterize the major NAT2 slow haplotype clusters (NAT2*14, NAT2*5,
NAT2*6 and NAT2*7, respectively). Individuals who are homozygous or compound
heterozygous for two of these low-activity haplotypes are classified as slow acetylators.
NAT2 acetylation has attracted much research interest in evolutionary biology and several
population genetic studies have attempted to clarify the role that slow acetylation could have
played in the adaptation of our species (Fuselli et al., 2007; Luca et al., 2008; Magalon et al.,
2008; Mortensen et al., 2011; Patin et al., 2006; Sabbagh and Darlu, 2006; Sabbagh et al.,
2011). The high prevalence of slow acetylators in humans (well above 50% worldwide) is
thought to be a consequence of the shift in modes of subsistence and lifestyle in the last
10,000 years, which triggered significant changes in diet and human exposure to xenobiotic
compounds. Several surveys of NAT2 sequence variation have indeed provided compelling
evidence that at least some of the slow-causing variants of NAT2 have been driven to presentday frequencies through the action of natural selection (Luca et al., 2008; Magalon et al.,

2008; Mortensen et al., 2011; Patin et al., 2006; Sabbagh et al., 2011). The slow acetylation
phenotype may thus have been a key adaptation to increase our species fitness in response to
the transition from foraging to farming.
Striking patterns of geographic differentiation have been described for the major NAT2
slow-causing variants (García-Martín, 2008; Sabbagh et al., 2011). The function of NAT2 in
mediating the interactions between humans and their chemical environment, which varies
depending on diet and lifestyle, makes it an excellent candidate for population-specific
selection pressures. Notably, an unusually high level of population differentiation between
East Asians and other populations (FST values around 0.40) has been described for the
c.341T>C slow-causing variant (rs1801280), as well as the two linked c.481C>T (rs1799929)
and c.803A>G (rs1208) nonfunctional SNPs, when compared to an empirical distribution of
FST computed across a 400-kb region encompassing the whole human NAT gene family
(Sabbagh et al., 2008). In contrast, the slow 590A variant (rs1799930) was found to occur at
roughly similar frequencies among widely dispersed populations (Luca et al., 2008; Sabbagh
et al., 2011). Such a low level of geographic differentiation may rather suggest a
homogenizing process of natural selection, promoting the same allelic variant in otherwise
disparate populations (through either directional or balancing selection). Although many
polymorphisms have been described in other regions of the NAT2 gene (Mortensen et al.,
2011; Patin et al., 2006), limited data exist on the geographic distribution of these variants in
worldwide populations.
In this study, we took advantage of the whole-genome sequence data available from the
1000 Genomes (1KG) project to explore the global patterns of population genetic
differentiation for the whole set of variants occurring in the entire NAT2 gene sequence (~10
kb). An outlier approach was used to determine whether the patterns of geographic
differentiation at this locus were atypical compared to those observed for the remaining

variation of the genome. Selection tests based on the site frequency spectrum and extended
haplotype homozygosity were further applied to determine the possible role of natural
selection in shaping the atypical patterns observed.

Materials and Methods
Data retrieval
Whole-genome variation data generated by the 1KG project in 1,089 unrelated
individuals

was

directly

downloaded

from

the

1000

Genomes

ftp

site

(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/), using the phase 1 integrated
release version 3 of April 2012 (1000 Genomes Project Consortium et al., 2012). The 1,089
individuals are drawn from 14 different populations in sub-Saharan Africa, Europe, East Asia,
and the Americas: Yoruba in Ibadan, Nigeria (YRI); Luhya in Webuye, Kenya (LWK);
people with African ancestry in the Southwest United States (ASW); Utah residents with
Northern and Western European ancestry (CEU); Tuscans in Italy (TSI); British in England
and Scotland (GBR); Finnish in Finland (FIN); Iberians in Spain (IBS); Han Chinese in
Beijing, China (CHB); Southern Han Chinese in China (CHS); Japanese in Tokyo, Japan
(JPT); people with Mexican ancestry in Los Angeles, California (MXL); Colombians in
Medellin, Colombia (CLM); and Puerto Ricans in Puerto Rico (PUR). From the obtained vcf
(variant call format) files, we extracted exclusively the low-coverage VQSR (Variant Quality
Score Recalibrator method) SNV calls in order to avoid any bias that might result from
differences between low-coverage whole-genome calls and high-coverage exome SNV calls.
Indels were not used. Functional annotation of the 36,382,866 SNVs retrieved was performed
using classification from the dbSNP database (build 137) (http://genome.ucsc.edu/cgibin/hgTables:SNV137.txt). SNVs were assigned to two main classes: genic and nongenic

SNVs. Genic SNVs were further classified as intronic, 5’-UTR, 3’-UTR, coding synonymous,
coding non-synonymous or splice-site.

Population genetic differentiation
Global levels of population genetic differentiation at NAT2 (chr8:18248755-18258723 in
the human GRCh37/hg19 assembly) were evaluated by using the fixation index FST (Wright,
1951) which quantifies the proportion of genetic variance explained by allele frequency
differences among populations. FST ranges from 0 (for genetically identical populations) to 1
(for completely differentiated populations). FST scores were computed for all NAT2 SNVs
occurring with a minor allele frequency (MAF) ≥ 0.05 in at least one of the 14 1KG
populations, using the BioPerl module PopGen (Stajich et al., 2002). Extreme values of FST
can result from natural selection but also from nonselective events linked to the demography
of populations, such as genetic drift. Because such nonselective processes randomly act on the
genome, they are expected to have the same average effect across the genome, in contrast to
natural selection, which impacts population differentiation in a locus-specific manner. The
genome-wide variation data provided by the 1KG project can thus be used to infer the action
of natural selection by adopting an outlier approach (Kelley et al., 2006). For that purpose, we
built eight empirical distributions of the FST statistic by considering different subsets of SNVs
defined according to their physical location and/or functional impact. To obtain distributions
of likely independent observations, a LD-based pruning procedure was applied to each of
these eight subsets using Plink (Purcell et al., 2007) with default parameters (pruning based on
a variance inflation factor of at least 2 within each sliding window of 50 SNVs with a step of
five SNVs). This resulted in a total of 25,532,386 independent autosomal SNVs included in
the genome-wide empirical distribution. These numbers are respectively 15,141,160,
11,282,100, 10,477,050, 24,395, 198,718, 107,644, 146,572, and 1,912 in the nongenic, genic,

intronic, 5’UTR, 3’UTR, coding synonymous, coding non-synonymous and splice-site
distributions. These eight distributions were then used as reference to assess whether the
patterns of genetic differentiation observed at NAT2 are atypical. Empirical P-values were
estimated as the proportion of FST scores in the empirical distribution that are either higher
(diversifying selection) or lower (homogenizing selection) than the value observed at the
locus of interest. Since FST strongly correlates with heterozygosity (Barreiro et al., 2008;
Beaumont and Nichols, 1996; Elhaik, 2012), empirical P-values were calculated within bins
of SNVs grouped according to their global MAF. A total of 27 bins were considered for the
whole MAF range: 10 bins of size 0.001 for MAF between 0 and 0.01, 9 bins of size 0.01 for
MAF between 0.01 and 0.10, and 8 bins of size 0.05 for MAF between 0.10 and 0.50.

Selection tests
To determine whether natural selection has played a role in the unusual patterns of
geographic differentiation disclosed, we used two complementary approaches based on the
allele frequency spectrum of segregating sites and on the local haplotype structure. Tajima’s
D (Tajima, 1989) is a classical neutrality test that compares estimates of the number of
segregating sites and the average number of pairwise differences between nucleotide
sequences (π). A zero value of the test statistic D is expected under the null hypothesis of
selective neutrality, whereas a positive D is taken as indicative of balancing selection and a
negative one of directional selection. Tajima’s D scores were computed across the whole
NAT2 coding region by using a sliding window approach with a window size of 1 kb and a
step size of 100 bp. Statistical significance of the test statistic was assessed using an empirical
approach. From the genome-wide data available from the 1KG project, we selected a set of
unlinked noncoding regions expected to be mostly neutrally evolving. A total of 100
autosomal regions of size 1kb were selected that met the following criteria: (i) to be at least

100 kb away from any known or predicted genes or expressed sequence tag or region
transcribed into mRNA; (ii) to be outside any segmental duplication or region transcribed into
a long noncoding RNA or conserved noncoding element, as defined in Woolfe et al. (Woolfe
et al., 2007); (iii) to be distant from each other by at least 100 kb and not in linkage
disequilibrium (LD) with each other; (iv) to contain a number of SNVs equal to the mean
number of SNVs included in the 1-kb sliding windows spanning the NAT2 coding region.
Tajima’s D scores were computed for these 100 regions so as to obtain the null (neutral)
distribution of the test statistic in each population sample. An empirical P-value was
estimated at each sliding window position within NAT2 by considering the proportion of
regions showing a test statistic greater (excess of intermediate-frequency variants) or lower
(excess of low-frequency variants) than the value observed at that specific position.
We next used methods based on the extended haplotype homozygosity (EHH)
measure, i.e. the sharing of identical alleles across relatively long distances by most
haplotypes in a population sample (Sabeti et al., 2002). We calculated the integrated
haplotype score (iHS) (Voight et al., 2006) that compares the rate of EHH decay observed for
both the derived and ancestral allele at each core SNV. An extremely positive or negative
value at the core SNV provides evidence of positive selection with unusually long haplotypes
carrying the ancestral or the derived allele, respectively. The raw iHS scores were computed
for all NAT2 SNVs using the iHS option implemented in the WHAMM! Software (Voight et
al., 2006), which we slightly modified in order to speed up computation times: thresholds for
EHH decay were modified from 0.25 to 0.15 and the size of the analyzed region was set to 0.2
Mb instead of 2.5 Mb. Information on ancestral allele state was obtained from a four-way
alignment of human, chimpanzee, orangutan and rhesus macaque species, provided by the
1KG

consortium (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/ance
stral_alignments/).
We also applied a cross-population test by computing the XP-EHH statistic (Sabeti et al.,
2007) that compares the integrated EHH computed in a test population versus that of a
reference population. XP-EHH scores were computed using the same EHH decay parameters
and window size as for iHS. The Yoruba (YRI) sample was used as a reference for samples
outside Africa, and the Utah residents of European ancestry (CEU) as a reference for African
samples.
iHS and XP-EHH scores were also computed for all available SNVs in the 100 neutral
regions described above, thus providing a reference distribution for each test statistic to
estimate empirical P-values. Raw scores of iHS and XP-EHH in NAT2 were standardized in
bins of derived allele frequency (step size of 0.05) using the corresponding distribution of
each statistic. For both iHS and XP-EHH, we used the phased data provided by the integrated
Phase 1 release version 3 of the 1KG project (April 2012) and genetic distances were obtained
from the high density genetic combined map based on 1KG pilot 1 data.

Estimation of the age of the derived allele at rs1799930
The age of the derived A allele at SNP rs1799930 was estimated using the maximum
likelihood method implemented in the Estiage software (Génin et al., 2004). This method was
originally developed to estimate the age of the most recent common ancestor of a rare
mutation involved in rare disease using microsatellite data. It is based on the length of
ancestral haplotype segments around the mutation shared by mutation carriers. Haplotypes in
a 20 kb region centered around rs1799930 were obtained from the phased 1000 Genome data.
Only SNV were considered and their genetic positions were obtained from the genetic maps
provided

on

the

Beagle

website

(http://bochet.gcc.biostat.washington.edu/beagle/genetic_maps/). Only one SNV every 0.01
cM was kept in the final analysis with Estiage. Age estimates were derived in each population
separately and a mutation rate of 10-3 per marker per individual per generation was assumed.
The mutation rate is a key parameter in Estiage that accounts for the fact that the most
proximal marker where a different allele from the ancestral haplotype is observed in an
individual might in fact not indicate a recombination but rather a mutation or a genotyping
error. For SNVs, mutation rates are assumed to be very low in the order of 10 -6 but
genotyping errors can be relatively high. A sensibility analysis was performed to choose the
value of the mutation rate in a range between 10-6 and 10-2 that gave coherent estimates
between the different populations and 10-3 was found to be the most plausible value.
Population allele frequencies at the different markers were estimated on the haplotypes not
carrying the A alleles at rs1799930.

In-silico prediction of SNV’s functional effects
The F-SNP method (Lee and Shatkay, 2008) (http://compbio.cs.queensu.ca/F-SNP/) was
applied to assess the potential functional effect of SNVs. This integrative scoring method
combines assessments from 16 independent computational tools and databases, using a
probabilistic framework that takes into account both the certainty of each prediction and the
reliability of the different tools depending on the physical and functional annotation of the
specific variant tested. It provides a functional significance (FS) score that quantitatively
measures the possible deleterious effect of the tested SNV at the splicing, transcriptional,
translational and post-translational levels. A FS score of 0.5 is considered as the cutoff point
for predicting a deleterious effect (Lee and Shatkay, 2009).

Results and Discussion
Global patterns of population genetic differentiation were examined in the genomic
region spanning the entire NAT2 gene (~10 kb), using the FST statistic (Wright, 1951) and the
sequence variation data provided by the 1KG project (1000 Genomes Project Consortium et
al., 2012). P-values were estimated from empirical distributions built from the background
genomic variation (see Materials and Methods). We assigned to each genetic variant of the
NAT2 gene a ‘main P-value’ derived from the genome-wide empirical distribution and a
‘subset P-value’ derived from the distribution including the subset of SNVs having a similar
location and/or functional impact than the SNV of interest (i.e., nongenic, intronic, 5’UTR,
3’UTR, coding synonymous, coding non-synonymous and splice site).
No SNVs in NAT2 exhibited significantly high FST values compared to the genomic
background, when considering the global differentiation among the 14 worldwide populations
from 1KG (all P-values > 0.05). No significant P-values were observed when contrasting East
Asia to the rest of the world either (data not shown). Although high FST scores were observed
for the three SNVs c.341T>C (rs1801280), c.481C>T (rs1799929) and c.803A>G (rs1208) in
this specific pairwise comparison (FST ≈ 0.30), they could not be considered as atypical when
compared to the rest of the genome (P-values ranging from 0.06 to 0.09). This contrasts with
previous findings pointing out an atypical pattern of differentiation for these three variants
when considering HapMap data and only the set of variants located within a 400-kb region
surrounding the NAT2 gene as a reference distribution (Sabbagh et al., 2008). This difference
may be due to the different set of populations surveyed or to the more accurate empirical
distribution used to represent the background genomic variation in the present study.
In contrast, five NAT2 SNVs exhibited unusually low FST values when compared to the
genome average, with both main and subset P-values below 0.05 (Figure 1). Four of them
(rs6984200, rs2087852, rs11996129 and rs1112005) are located in the intronic region of

NAT2, while the fifth one (rs1799930) is a non-synonymous substitution defining the NAT2*6
slow haplotype cluster (c.590G>A resulting in R197Q). Note that the four intronic SNVs are
in high LD with the rs1799930 variant (r2 ranging from 0.80 to 0.88) (Table 1). They all occur
at high frequencies in the global human population (within the 0.23-0.26 MAF range). Such
low levels of population genetic differentiation suggest that at least one of these
polymorphisms may be subject to balancing or species-wide directional selection, the
rs1799930 being the most likely target given its gene location and functional impact.
To determine whether another putative candidate in the genomic region surrounding
NAT2 might explain the patterns observed, through a significant LD with these variants, we
extended the analysis to a 600-kb region centered on the human NAT multigene family on
chromosome 8 (Figure 2). All the variants exhibiting an r2 value above the 0.10 threshold
with the rs1799930 SNV are located within a 56-kb region (chr8:18229877-18285763 in
hg19) in the direct vicinity of the NAT2 gene (Figure 2A), making unlikely the involvement of
another gene in the region. Table 1 provides the list of variants showing a significantly low
interpopulation FST value for either the main or subset P-value and being in moderate to
strong LD with the rs1799930 variant (r2 > 0.50). They are all either intergenic (located up to
~3 kb upstream or 22 kb downstream of the NAT2 gene) or intronic to NAT2. The prediction
of their functional impact with the F-SNP method revealed high FS scores for some of them
(FS = 0.50), denoting a potentially deleterious effect by affecting either the transcriptional or
splicing regulation. However, the highest FS score was observed for the rs1799930
polymorphism (0.87), which also displayed the lowest subset P-value (P = 0.016; Table 1).
Altogether, these results point to the rs1799930 polymorphism as the most likely target of
homogenizing selection in the genomic region surveyed.
Interestingly, recent evidence suggest that the NAT2*6 haplotype cluster (characterized
by the rs1799930 A slow-causing allele) is related with the slowest acetylation capacity in

vivo, and that the homozygous genotype NAT2*6/*6 thus defines a new category of ‘ultraslow’ acetylators (Ruiz et al., 2012; Selinski et al., 2013). Ultra-slow acetylators have about
30% lower activities of caffeine metabolism compared with other slow acetylators. This is of
the same order of magnitude than the reduction in enzyme activity between rapid and
intermediate acetylators (Ruiz et al., 2012). These findings are consistent with a previous
study by Cascorbi et al. (Cascorbi et al., 1995) that demonstrated a markedly decreased NAT2
activity in vivo in NAT2*6/*6 compared to NAT2*5/*5 genotypes. Indirect evidence is also
provided by clinical association studies related to both drug toxicity and cancer risk. Antituberculosis drug-induced hepatotoxicity risk has been shown to be particularly high in
carriers of the NAT2*6/*6 genotype (An et al., 2012; Huang et al., 2002; Lee et al., 2010;
Leiro-Fernandez et al., 2011; Selinski et al., 2014; Teixeira et al., 2011). Similarly, the ultraslow genotype, and not the common slow NAT2 genotype, has been significantly associated
with an increased risk of urinary bladder cancer (Selinski et al., 2013). Altogether, both in
vivo phenotyping studies and clinical reports suggest that the NAT2*6 variant is likely to be
associated with a specific acetylation phenotype. This could explain why this particular NAT2
slow-causing variant, and not another one, may have been a specific target of natural
selection.
Although a highly homogenous distribution of the rs1799930 A allele is observed across
worldwide populations (with a global frequency of 0.246), resulting in an unusually low FST
value (interpopulation FST = 0.006), a three-fold lower frequency of this allele has been
reported in hunter-gatherers (~ 0.08) as compared to agriculturalists and pastoralists (~ 0.25)
in a comprehensive survey of human NAT2 variation including 128 population samples
classified according to their major subsistence strategy (Sabbagh et al., 2011). This significant
difference in the frequency of NAT2*6 alleles (P < 0.0001) was identified as the main genetic
cause of the higher prevalence of the slow acetylation phenotype in populations practicing

farming and herding as compared to those mostly relying on hunting and gathering (46% vs
22%, respectively) (Sabbagh et al., 2011). Given this marked correlation between the
rs1799930 A allele and the subsistence strategy adopted by past populations in the last 10,000
years, it has been suggested that this slow-causing allele may have conferred a selective
advantage in populations shifting from foraging to agricultural and pastoral activities in the
Neolithic period. New or more concentrated NAT2 substrates introduced in the chemical
environment of food-producing communities have likely promoted a slower acetylation rate in
these populations. This hypothesis is further supported by the age estimation of the rs1799930
A allele in the 1KG populations provided by a maximum-likelihood method implemented in
the Estiage software (Génin et al., 2004) (Table 2). Our estimations showed that this allele
started to increase in frequency at similar and recent times in all populations, roughly between
~1,500 and 6,000 years ago, thereby supporting a global expansion since the emergence of
agriculture in the Neolithic. Consequently, the markedly low level of population
differentiation observed at the rs1799930 locus may result from the convergent selection of
the rs1799930 A allele in agriculturalist and pastoralist populations which are now present in
most parts of the world.
Several lines of evidence support the hypothesis that the rs1799930 G>A nonsynonymous substitution (R197Q) has specifically occurred in the human lineage. First, the
NAT2 197R residue appears to be highly conserved throughout primate evolution, with 100%
of the orthologous NAT2 sequences generated in 19 distinct simian species harboring an
arginine (R) at this position (Sabbagh et al., 2013). Second, the 197R position was found to be
monomorphic in 103 individuals from six great ape species (Pan troglodytes, Pan paniscus,
Gorilla beringei, Gorilla gorilla, Pongo abellii, Pongo pygmaeus) (Prado-Martinez et al.
(Prado-Martinez et al., 2013), E.S. Poloni, personal communication), as well as in 28 Rhesus
monkeys (Macaca mulatta) fully sequenced for the NAT2 gene (A. Sabbagh, personal

communication), making the R197Q polymorphism a specific feature of the human lineage.
The hypothesis of a trans-species polymorphism maintained for several million years, through
shared balancing selection pressures, seems therefore unlikely.
Assuming that the rs1799930 A allele has conferred a selective advantage to populations
shifting from food collection to farming and animal breeding in the Holocene, this could have
happened either through directional selection or balancing selection. A gene-dose effect has
been indeed described for this variant, with a significant trend toward a slower acetylation
capacity in individuals carrying an increasing number of NAT2*6 haplotypes (0, 1 or 2) (Ruiz
et al., 2012; Selinski et al., 2013). Therefore, heterozygous individuals for this allele display
an intermediate metabolic phenotype that may have been advantageous if one considers the
competing needs of both maintaining an efficient detoxification of harmful xenobiotics and
avoiding the damaging effects of the putative carcinogens that can be activated through NAT2
acetylation. In an attempt to provide further insights into the evolutionary mechanisms that
might have driven and maintained the rs1799930 A allele at high frequencies in most human
populations worldwide, we carried out several tests of selective neutrality based on the allele
frequency spectrum: Tajima’s D (Tajima, 1989) and haplotype structure: iHS (Voight et al.,
2006) and XP-EHH (Sabeti et al., 2007). An empirical approach using sequence variation data
from 100 unlinked noncoding regions was adopted to assess statistical significance.
All iHS and XP-EHH scores computed for the rs1799930 SNV in all individual
populations from 1KG were not significant at the 0.05 threshold (Table 3). This precludes a
clear signal of positive selection for this variant as the one expected under a ‘hard sweep
model’, which assumes the rapid fixation of a single newly arisen advantageous mutation
(Pritchard et al., 2010). In contrast, we found significant Tajima’s D scores in the 1-kb regions
encompassing the rs1799930 variant in five population samples: British, Finnish, Tuscans,
Utah residents of European ancestry and Puerto Ricans (P < 0.05) (Tables 3 and 4). We

acknowledge that these results become non-significant when a correction for multiple testing
is applied, but we also note that the ratio of five significant tests out of 14 is higher than the
expected 5% proportion of false positives. Non-significant scores, but with P-values getting
closer to the 5% threshold, were observed in two additional samples (P = 0.07 and P = 0.08 in
Colombians and Luhya, respectively). Furthermore, although non-significant scores prevent
rejection of the null hypothesis of selective neutrality, it is noteworthy that all populations
tested but one (Japanese) gave positive Tajima’s D values, suggesting a trend toward an
excess of intermediate-frequency variants compatible with the action of balancing selection.
Such consistent results for populations with different demographic pasts make it unlikely that
they are due to demography rather than balancing selection. This is also in agreement with
previous findings demonstrating globally positive and significant Tajima’s D values in
different continental populations and the absence of any signature of positive selection, as
detected by EHH-based tests (Fuselli et al., 2007; Luca et al., 2008; Magalon et al., 2008;
Mortensen et al., 2011). A notable exception concerns the c.341C>T slow-causing variant for
which a selective sweep was detected in Western and Central Eurasian populations (Patin et
al., 2006) with the long-range haplotype test (Sabeti et al., 2002). We did not confirm such
signature of positive selection at this locus in any of the 14 populations from 1KG (both iHS
and XP-EHH scores not significant at the 0.05 level). No significant scores were observed for
any of the other slow-causing variants either (c.191G>A, c.341T>C and c.857G>A; data not
shown). Therefore, patterns of diversity at NAT2 seem compatible with either balancing
selection or a more complex model of ‘multiallelic’ directional selection where different slow
variants of NAT2 may have simultaneously become targets of directional selection, thereby
generating an excess of intermediate-frequency alleles. This would explain why our
conventional tests of selection based on EHH, more suited to detect classical selective sweeps,
failed to detect a signature of positive selection at the rs1799930 locus. The signature of

selection at this individual position could have been weakened by the global increase in
frequency of other NAT2 altering mutations. Note, however, that contrary to c.191G>A
(NAT2*14), c.341T>C (NAT2*5) and c.857G>A (NAT2*7), which mainly cluster in specific
continental regions (sub-Saharan Africa, Europe and Asia, respectively (Sabbagh et al., 2011),
the cosmopolitan distribution of the c.590G>A variant (NAT2*6) suggests that it may have
been positively selected in globally distributed food-producing communities. Finally, the
hypotheses of balancing and directional selection are not mutually exclusive and multiple
modes of selection may have operated at the NAT2 locus on a population-specific basis, as
previously suggested (Mortensen et al., 2011).
In conclusion, we have described an atypical pattern of geographic differentiation for
five genetic variants of the NAT2 gene, including the functional rs1799930 SNP defining the
slow NAT2*6 haplotype series, and four intronic SNPs in high LD with it. An extended
analysis of a 600-kb region surrounding NAT2 pointed to the rs1799930 polymorphism as the
most likely target of a homogenizing process of natural selection promoting the same allelic
variant in most human populations, resulting in an unusually low FST value (FST = 0.006). The
rs1799930 A allele has been associated with the slowest acetylation capacity in vivo and is
much more frequent in agriculturalists and pastoralists as compared to hunter-gatherers,
suggesting it may have been positively selected in food-producing communities which are
now present in most parts of the world. Neutrality tests based on the allele frequency
spectrum revealed a trend toward an excess of intermediate-frequency variants at NAT2,
compatible with either balancing selection or a more complex model of multiallelic
directional selection. Our findings provide further insights into the functional importance of
the rs1799930 polymorphism and the role it may have played in human adaptation to
fluctuating xenobiotic environments.
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Table 1. List of variants in the 600-kb region surrounding the NAT2 gene with
significantly low FST values and in high linkage disequilibrium with rs1799930
SNV

Physical
position on
chr 8 (hg19)

Functional
annotation

Distance
Global
from NAT2 MAF
(kb)

Interpopulation
FST

Main
P-value

Subset
P-value

r2 with
Functional
rs1799930 significance score
(F-SNP)

rs11992530
rs4646241
rs4646242
rs4646244
rs6984200
rs2087852
rs11996129
rs1112005
rs1799930

18246133
18246696
18247449
18247718
18250317
18251926
18254575
18255876
18258103

2.6
2.1
1.3
1.0
0
0
0
0
0

0.254
0.247
0.246
0.246
0.255
0.235
0.236
0.227
0.246

0.006
0.007
0.006
0.006
0.007
0.007
0.005
0.005
0.006

0.024
0.032
0.025
0.026
0.028
0.032
0.021
0.019
0.026

0.024
0.034
0.024
0.025
0.028
0.031
0.020
0.019
0.016

0.80
0.83
0.84
0.84
0.80
0.86
0.85
0.88
-

no known function
no known function
0.50
no known function
0.50
0.50
0.37
0.50
0.87

rs4646247
rs721398
rs45605031
rs872233

18258908
18259305
18260239
18280686

Intergenic
Intergenic
Intergenic
Intergenic
Intronic
Intronic
Intronic
Intronic
Coding nonsynonymous
Intergenic
Intergenic
Intergenic
Intergenic

0.2
0.6
1.5
22.0

0.247
0.244
0.248
0.274

0.006
0.005
0.006
0.007

0.025
0.019
0.024
0.030

0.024
0.020
0.026
0.032

0.99
0.97
0.98
0.76

0.50
no known function
no known function
no known function

SNV, single nucleotide variant; MAF, minor allele frequency. Only variants with r2 > 0.50
with rs1799930 are shown. SNVs located in the NAT2 gene are shaded in grey. A functional
significance score of 0.5 is considered as the cutoff point for predicting a deleterious effect
(Lee and Shatkay, 2009).

Table 2. Estimation of the age of the derived allele at rs1799930
Population

Number of
carrier
haplotypes

Age in
generations
[95%CI]

Age in years [95%CI]
(1 generation = 20
years)

YRI

40

294 [231-376]

5880 [4620-7520]

LWK

56

139 [111-174]

2780 [2220-3480]

ASW

34

202 [154-267]

4040 [3080-5340]

IBS

4

162 [76-356]

3240 [1520-7120]

TSI

54

129 [104-160]

2580 [2080-3200]

CEU

50

310 [250-386]

6200 [5000-7720]

GBR

51

74 [59-93]

1480 [1180-1860]

FIN

52

77 [61-188]

1540 [1220-3760]

JPT

43

101 [79-130]

2020 [1580-2600]

CHB

37

237 [184-308]

4740 [3680-6160]

CHS

49

203 [164-253]

4060 [3280-5060]

CLM

27

136 [100-188]

2720 [2000-3760]

MXL

16

138 [92-223]

2760 [1840-4460]

PUR

22

173 [124-248]

3460 [2480-4960]

The age of the derived A allele at SNP rs1799930 was estimated using the maximum
likelihood method implemented in the Estiage software (Génin et al. 2004). YRI: Yoruba
from Ibadan, Nigeria; LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry
from the southwestern United States; IBS: Iberian populations from Spain; TSI: Tuscans from
Italy; CEU: Utah residents with Northern and Westhern European ancestry; GBR: British
from England and Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan;
CHB: Han Chinese from Beijing; CHS: Han Chinese from South China; CLM: Colombians
from Medellín, Colombia; MXL: people of Mexican ancestry from Los Angeles, California;
PUR: Puerto Ricans from Puerto Rico.

Table 3. Results of selection tests for the NAT2 rs1799930 polymorphism
YRI

Africa
LWK

ASW

IBS

TSI

Europe
CEU

GBR

FIN

JPT

Asia
CHB

CHS

CLM

America
MXL

PUR

iHS

0.18

-0.27

-0.05

-0.82

-0.08

0.17

0.02

-0.19

0.18

-0.11

0.06

0.33

0.09

-0.29

XP-EHH

-0.80

0.11

-0.50

1.38

0.54

0.80

0.68

0.42

0.20

0.42

0.02

0.19

0.07

0.13

Tajima's D a

0.33

1.00*

0.60

1.07

2.58**

-0.03

0.91

0.88

1.65*

0.99

1.55**

2.49** 3.28*** 2.67**

Significant scores at the 0.05 threshold are shown in bold. YRI: Yoruba from Ibadan, Nigeria;
LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry from the southwestern
United States; IBS: Iberian populations from Spain; TSI: Tuscans from Italy; CEU: Utah
residents with Northern and Westhern European ancestry; GBR: British from England and
Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan; CHB: Han Chinese
from Beijing; CHS: Han Chinese from South China; CLM: Colombians from Medellín,
Colombia; MXL: people of Mexican ancestry from Los Angeles, California; PUR: Puerto
Ricans from Puerto Rico.
*

P ≤ 0.10, ** P ≤ 0.05, *** P ≤ 0.01

a

Highest Tajima’s D score observed in the 1-kb sliding windows spanning the rs1799930

nucleotide position in each individual population. Note that, except in Asians (Japanese and
both Han Chinese samples), Luhya and African-Americans, these scores also correspond to
the highest values observed across the whole NAT2 coding region (Table 3).

Table 4. Tajima’s D scores in the 1-kb sliding windows spanning the whole NAT2 coding region
Starta

Enda

Slow -causing variant(s) included in the
w indow b

YRI

LWK

ASW

IBS

TSI

CEU

GBR

FIN

JPT

CHB

CHS

CLM

MXL

PUR

18256555

18257555

none

0.12

-0.37

-0.40

-0.10

0.38

0.21

0.52

-0.45

-0.96

-1.17

-1.41

-0.27

-0.91

-0.23

18256655

18257655

none

0.16

-0.31

-0.32

-0.10

0.38

0.58

0.88

-0.26

-0.96

-1.17

-1.41

0.03

-0.78

0.32

18256755

18257755

c.191G>A

0.55

-0.28

0.04

0.46

0.38

0.78

0.92

0.02

-1.32

-1.05

-1.09

0.08

-0.67

0.23

18256855

18257855

c.191G>A, c.341T>C

1.22*

0.55

0.84

0.67

1.32

1.71

1.85

0.96

-0.61

-0.24

-0.26

0.93

0.09

1.10

18256955

18257955

c.191G>A, c.341T>C

0.94

0.41

0.55

0.67

1.32

1.71

1.85

0.96

-0.61

-0.24

-0.26

0.93

0.09

0.73

18257055

18258055

c.191G>A, c.341T>C

0.69

0.36

0.43

0.67

1.32

1.72

2.46**

1.35

-0.86

-0.24

-0.26

0.91

0.09

0.71

18257155

18258155

c.191G>A, c.341T>C, c.590G>A

0.33

0.82

0.60

0.58

1.57

1.95

3.28***

2.01*

-0.42

0.11

0.18

1.50*

0.13

1.14

18257255

18258255

c.191G>A, c.341T>C, c.590G>A

0.29

0.83

0.60

0.58

2.02

2.49**

3.28***

2.01*

-0.42

0.11

0.18

1.50*

0.13

1.14

18257355

18258355

c.191G>A, c.341T>C, c.590G>A

0.31

0.73

0.29

0.58

2.58**

2.49**

3.28***

2.01*

-0.42

0.11

0.19

1.50*

0.67

1.55**

18257455

18258455

c.191G>A, c.341T>C, c.590G>A, c.857G>A

0.17

1.00*

0.19

1.07

2.06

1.95

2.64***

2.67**

-0.37

0.35

0.78

1.65*

0.96

1.37*

18257555

18258555

c.191G>A, c.341T>C, c.590G>A, c.857G>A

-0.007

0.53

0.008

0.70

1.71

1.61

2.23*

2.18*

-0.12

0.35

0.78

1.28

0.99

1.13

18257655

18258655

c.191G>A, c.341T>C, c.590G>A, c.857G>A

-0.007

0.53

0.008

0.70

1.71

1.61

2.23*

2.18*

-0.12

0.35

0.78

1.28

0.99

1.13

18257755

18258755

c.341T>C, c.590G>A, c.857G>A

-0.04

0.58

0.06

0.70

2.16*

1.61

2.23*

2.18*

-0.12

0.35

0.41

1.28

0.99

1.51*

18257855

18258855

c.590G>A, c.857G>A

-0.70

-0.18

-0.62

0.54

0.96

0.87

1.51

1.44

-0.49

0.01

-0.007

0.61

0.03

0.83

18257955

18258955

c.590G>A, c.857G>A

-0.42

0.05

-0.47

0.45

1.27

1.21

1.81

1.73

-0.03

0.32

0.39

0.83

0.36

0.97

18258055

18259055

c.590G>A, c.857G>A

-0.82

-0.78

-0.88

0.10

0.22

-0.11

0.68

0.62

0.64

0.91

0.88

0.05

-0.22

0.21

18258155

18259155

c.857G>A

-0.67

-1.12

-1.05

0.14

-0.17

-0.51

0.29

0.23

0.23

0.70

0.54

-0.23

-0.03

0.004

18258255

18259255

c.857G>A

-0.47

-1.01

-0.92

0.14

-0.17

-0.51

0.29

0.23

-0.16

0.70

0.54

-0.23

-0.03

0.004

18259355

c.857G>A

-0.54

-0.90

-0.77

-0.79

-0.35

-0.61

0.12

0.07

0.58

1.42

1.20

-0.13

-0.51

-0.27

18258355

Africa

Europe

Asia

America

YRI: Yoruba from Ibadan, Nigeria; LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry from the southwestern United States;
IBS: Iberian populations from Spain; TSI: Tuscans from Italy; CEU: Utah residents with Northern and Westhern European ancestry; GBR:
British from England and Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan; CHB: Han Chinese from Beijing; CHS: Han

Chinese from South China; CLM: Colombians from Medellín, Colombia; MXL: people of
Mexican ancestry from Los Angeles, California; PUR: Puerto Ricans from Puerto Rico.
*

P ≤ 0.10, ** P ≤ 0.05, *** P ≤ 0.01

a

Genomic position of each 1-kb window on chromosome 8 in the human GRCh37/hg19

assembly.
b

The four slow causing variants c.191G>A, c.341T>C, c.590G>A and c.857G>A correspond

to the rs1801279, rs1801280, rs1799930, rs1799931 SNPs, respectively.
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Figure Captions
Figure 1. Distribution of -log10 (P-values) of interpopulation FST scores across the human
NAT2 gene. FST scores were computed among the 14 worldwide populations from the 1000
Genomes project. P-values were estimated from the lower tail of the empirical distributions.
(A) Main P-value derived from the genome-wide empirical distribution (including 25,532,386
SNVs). (B) Subset P-value derived from the empirical distribution including the subset of
SNVs having a similar location and/or functional impact than the SNV of interest (i.e.,
intronic, 3’UTR, coding synonymous, and coding non-synonymous). The red dotted line
indicates the 0.05 significance threshold.
Figure 2. Distribution of -log10 (P-values) of interpopulation FST scores across a 600-kb
region centered on the human NAT gene family for those variants in linkage
disequilibrium (r2 > 0.10) with the rs1799930 polymorphism. (A) Level of linkage
disequilibrium, as measured by the r2 statistic (Hill, 1968), with the rs1799930 genetic
variant. (B) Main P-value estimated from the lower tail of the genome-wide empirical
distribution (including 25,532,386 SNVs). (C) Subset P-value estimated from the lower tail
of the empirical distribution including the subset of SNVs having a similar location and/or
functional impact than the SNV of interest (i.e., nongenic, intronic, 5’UTR, 3’UTR, coding
synonymous, coding non-synonymous and splice site). The red dotted line indicates the 0.05
significance threshold. SNVs are displayed in different colors according to their r2 value with
rs1799930, ranging from dark blue (r2 = 0.10) to dark red (r2 = 1.0). The rs1799930
polymorphism is represented as a black triangle. Coding genes and pseudogenes in the 600-kb
region are represented below as dark grey and light grey boxes, respectively. The genomic
position (in megabases) on chromosome 8 is indicated on the horizontal axis (human
GRCh37/hg19 assembly).

Figure 3. Distribution of rs1799930 (c.590G>A) allele frequencies in human populations.
Allele frequency data for the rs1799930 SNP were collected for 146 worldwide samples by
performing an extensive survey of the literature. Description of samples and retrieved allele
frequency data are provided in Table S1. Only those samples composed of at least 20
individuals (N = 105) were represented on the map. Samples are numbered as reported in
Table S1 (‘sample ID’). Six samples could not be localized on the map because of unspecified
sampling location (sample 70) or because of divergence between sampling location and
region of origin (samples 42, 55, 60, 61, and 102); these samples are displayed in a box
beneath the caption.

